Trial Profile
A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of GRC 8200, a New Oral DPP IV Inhibitor, in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Melogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 18 Oct 2009 Results presented at the 20th World Diabetes Congress (WDC).
- 25 Sep 2009 Planned end date changed from 1 May 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
- 24 Jun 2009 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met, according to results reported in a Glenmark media release.